Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.
The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.
Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.
Latest News:
- A photo accompanying this announcement is available
- Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
- Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) has appointed Thomas Hoover as the Chief Business Officer, focusing on business and corporate development. Hoover brings nearly 20 years of biopharmaceutical experience, including previous roles at Millendo Therapeutics and Sunovion. CEO Jerome D. Jabbour expressed confidence in Hoover's ability to advance the company's lipid nanocrystal (LNC) platform during this critical period. Matinas is developing multiple LNC formulations, including MAT2203 for invasive fungal infections and MAT2501 for bacterial infections, and plans to partner further on its omega-3 therapy, LYPDISO.
Matinas BioPharma Holdings (NYSE: MTNB) has been invited to present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will showcase its innovative lipid nanocrystal (LNC) delivery platform and will hold investor meetings. A pre-recorded presentation will be available on the company’s IR Calendar page starting November 22, 2021, at 10:00 a.m. ET. Additionally, CEO Jerome D. Jabbour will lead a fireside chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series on November 23, 2021, at 12:30 p.m. ET.
Matinas BioPharma Holdings (MTNB) reported positive results from the first two cohorts of its EnACT study for MAT2203, an oral treatment for cryptococcal meningitis, prompting the DSMB to recommend progressing in the study. Additionally, the company initiated a Phase 1 study for MAT2501, an oral aminoglycoside antibiotic. Financially, MTNB reported a net loss of $6.8 million for Q3 2021, consistent with the previous year. The company believes it has sufficient cash reserves of $53.8 million to fund operations into 2024. Kathryn Penkus Corzo joined the Board of Directors.
Matinas BioPharma Holdings (MTNB) will host a conference call on November 8, 2021, at 8:30 a.m. ET to discuss its Q3 2021 operational and financial results. To join, call (877) 407-5976 (toll-free) or (412) 902-0031 (toll), using conference ID 13723555. The call will also be webcast on their website, where it will be archived for 90 days. Matinas specializes in a lipid nanocrystal delivery platform for therapeutics, with ongoing studies for drug candidates MAT2203 and MAT2501, targeting fungal and bacterial infections respectively.
Matinas BioPharma Holdings has been selected for the B. Riley Fall 2021 Growth Biotech Best Ideas Series. CEO Jerome D. Jabbour will lead a fireside chat on November 23, 2021, at 12:30 p.m. ET, discussing their innovative lipid nanocrystal platform aimed at effective intracellular drug delivery for serious diseases. The company is advancing multiple product candidates, including MAT2203 for fungal infections and MAT2501 for bacterial infections, both benefiting from unique delivery technology. A viewing option for the chat will be available on their website.
Matinas BioPharma Holdings (NYSE AMER: MTNB) has initiated a Phase 1 study of MAT2501, an oral formulation of amikacin, with the first patient dosed. The trial aims to assess safety, tolerability, and pharmacokinetics, completing enrollment by Q1 2022 and reporting data in Q2 2022. MAT2501 targets nontuberculous mycobacterial infections and marks a significant advancement as a potential first oral aminoglycoside. Supported by a $4.2 million award from the Cystic Fibrosis Foundation, MAT2501 has received FDA designations that could provide up to 12 years of marketing exclusivity if approved.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) announced the nomination of Kathryn Penkus Corzo for election to its Board of Directors at the 2021 Annual Meeting on November 1, 2021. Corzo, a partner at Takeda Ventures and former Head of Oncology Cell Therapy Development at Takeda, brings over 25 years of experience in biopharma. The company also noted that Patrick LePore will not seek re-election. Notable advancements include positive EnACT data for MAT2203, showing 95% survival in HIV patients with cryptococcal meningitis.
Matinas BioPharma (MTNB) presented its company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is available on-demand via their investor website. Matinas focuses on the intracellular delivery of therapeutics using its lipid nanocrystal (LNC) platform. Their lead product, MAT2203, an oral formulation of amphotericin B, shows promising Phase 2 results in HIV patients with cryptococcal meningitis. Additionally, MAT2501 is set to enter Phase 1 trials for treating bacterial infections.
Matinas BioPharma (MTNB) announced positive results from the EnACT trial of MAT2203 for treating cryptococcal meningitis. Early Fungicidal Activity (EFA) reached 0.38 log10 CFU/mL/day, surpassing the target of >0.20, indicating effective fungal clearance. A 95% overall survival rate was observed in Cohort 2 with no breakthrough infections. MAT2203 showed no kidney toxicity or electrolyte issues during 6 weeks of treatment. The Data Safety Monitoring Board supports advancing to Cohort 3, with enrollment underway, and the company plans to seek FDA engagement for early approval.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) announced a Notice of Allowance from the USPTO for its oral formulation MAT2203, an antifungal medicine. This patent, covering a combination of amphotericin B and additional antifungal agents for treating central nervous system infections, extends patent protection to 2037. The company now holds six issued U.S. patents and 25 patents for its lipid nanocrystal platform, enhancing MAT2203's commercial potential. MAT2203 is currently in a Phase 2 clinical trial for cryptococcal meningitis in HIV patients, with further studies expected.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
What is Matinas BioPharma Holdings, Inc.?
What is MAT2203?
What is MAT2501?
What technology does Matinas BioPharma use?
What are the benefits of MAT2203?
What types of infections does MAT2501 target?
What is unique about Matinas BioPharma's approach?
Who can I contact for investor relations inquiries?
What is the status of MAT2203 clinical trials?
What recent achievements has Matinas BioPharma reported?
